Merus (MRUS) Projected to Post Quarterly Earnings on Wednesday

Merus (NASDAQ:MRUS) is anticipated to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $10.57 million for the quarter.

Merus Trading Up 5.1 %

NASDAQ MRUS opened at $42.27 on Wednesday. The business’s 50 day moving average is $41.48 and its two-hundred day moving average is $47.05. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -10.70 and a beta of 1.11.

Analyst Ratings Changes

A number of research firms recently weighed in on MRUS. UBS Group began coverage on Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 price target on the stock. The Goldman Sachs Group began coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target on the stock. Citigroup upped their price target on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Needham & Company LLC restated a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Monday, December 9th. Finally, Wells Fargo & Company began coverage on Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price target on the stock. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $85.92.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.